{"id":"NCT02452047","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)","officialTitle":"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Estimate the Efficacy and Safety of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium + Imipenem/Cilastatin in Subjects With Imipenem-Resistant Bacterial Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08-21","primaryCompletion":"2017-09-18","completion":"2017-09-18","firstPosted":"2015-05-22","resultsPosted":"2018-10-19","lastUpdate":"2018-10-19"},"enrollment":50,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Bacterial Infections"],"interventions":[{"type":"DRUG","name":"Imipenem+Cilastatin/Relebactam","otherNames":["MK-7655A"]},{"type":"DRUG","name":"Colistimethate sodium (CMS)","otherNames":[]},{"type":"DRUG","name":"Imipenem+Cilastatin","otherNames":[]},{"type":"DRUG","name":"Placebo to CMS","otherNames":[]}],"arms":[{"label":"Group 1: Imipenem+Cilastatin/Relebactam","type":"EXPERIMENTAL"},{"label":"Group 2: Colistimethate sodium + Imipenem+Cilastatin","type":"ACTIVE_COMPARATOR"},{"label":"Group 3: Imipenem+Cilastatin/Relebactam","type":"EXPERIMENTAL"}],"summary":"The study will evaluate the efficacy and safety of imipenem+cilastatin/relebactam (MK-7655A) versus colistimethate sodium+imipenem+cilastatin in the treatment of imipenem-resistant bacterial infections. Infections evaluated in the study will be hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), complicated intra-abdominal infection (cIAI), and complicated urinary tract infection (cUTI).","primaryOutcome":{"measure":"Percentage of Participants With Favorable Overall Response (FOR)","timeFrame":"Up to Day 30 (up to 9 days after completing study treatment)","effectByArm":[{"arm":"Group 1: Imipenem+Cilastatin/Relebactam","deltaMin":71.4,"sd":null},{"arm":"Group 2: Colistimethate Sodium + Imipenem+Cilastatin","deltaMin":70,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":9},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["32154325","32094127","31400759"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":31},"commonTop":["Pyrexia","Nausea","Aspartate aminotransferase increased","Anaemia","Alanine aminotransferase increased"]}}